Outcomea | MSD | MUD | Haplo | p |
---|---|---|---|---|
Acute GvHD, % (95% CI) | Â | Â | Â | Â |
 Grade II–IV | 34 (23–45) | 41 (30–51) | 32 (27–38) | 0.4 |
 Grade III–IV | 15 (8–24) | 15 (9–24) | 13 (9–17) | 0.8 |
Chronic GvHD, % (95% CI) | Â | Â | Â | Â |
 Overall | 42 (29–54) | 50 (37–61) | 35 (29–41) | 0.01 |
 Extensive | 21 (12–33) | 17 (9–27) | 11 (7–15) | 0.2 |
NRM, % (95% CI) | 21 (12–32) | 18 (10–27) | 21 (17–26) | 0.8 |
RI, % (95% CI) | 28 (17–41) | 20 (12–30) | 20 (16–26) | 0.8 |
LFS, % (95% CI) | 51 (37–63) | 62 (50–72) | 59 (52–64) | 0.8 |
OS, % (95% CI) | 62 (48–73) | 69 (57–79) | 66 (60–72) | 0.8 |
GRFS, % (95% CI) | 35 (23–47) | 44 (32–55) | 46 (40–52) | 0.9 |